Novella Clinical announces acquisition of Prologue

Novella Clinical announced today the acquisition of Prologue Research International, Inc. (Prologue) an Ohio-based full service Clinical Research Organization (CRO) that focuses exclusively on oncology drug development. "The acquisition of Prologue strengthens our oncology therapeutic franchise and is a strategic addition to our earlier announced deal this year with OSI Pharmaceuticals," says Richard Staub, President and Chief Executive Officer. Mr. Staub continues, "Prologue's experience includes the management of more than 120 oncology trials across a wide variety of indications with a customer base that does not overlap with Novella Clinical's. With Prologue, Novella will expand its support to oncology Sponsors with the creation of a dedicated business unit focused exclusively on oncology drug development, with the objective of bringing much needed products to market to improve the lives of people with cancer."

“The acquisition of Prologue strengthens our oncology therapeutic franchise and is a strategic addition to our earlier announced deal this year with OSI Pharmaceuticals”

Tom Ludlam, Prologue's President and CEO, states, "We are excited to be joining forces with Novella Clinical. Combining Prologue's experienced oncology team with Novella Clinical's oncology team, their infrastructure and e-based technology allows us to better serve current and future customers in the design and execution of complex oncology programs across geographic regions. As important, Novella Clinical and Prologue share a common culture, centered on customer service and executional excellence."

Both Novella Clinical and Prologue Research have been providing contract research services for biotechnology, pharmaceutical and device companies for 12 years. The acquisition will add approximately 60 staff to Novella's global base of 738 professionals, and an office located in Columbus, Ohio.